Table 1.
A select list of published laboratory and clinical assessments of IC‐based immune therapy and vaccination
| Complex | Species | Disease targeted/model | Observations | References (authors, year) |
|---|---|---|---|---|
| Antitumor | ||||
| Specific mIgG2A/hCD20 | Mouse (humanized) | EL4 expression hCD20 | Tumor clearance; via ADCC; FcγRIV is required; engineered selective engagement of hFcγRIII is effective | DiLillo and Ravetch (2015) |
| Specific mIgG1/NYU‐seo‐1 | Mouse | Colon epithelial tumor | Tumor inhibition; CD8 required; enhanced by chemotherapy; epitope spreading | Noguchi et al (2012) |
| Fusion of OVA to anti‐DEC205 antibody, DEC205 targeting etc. | Mouse | B16, HER2‐neu bearing tumor | Enhanced tumor resistance, involvement of both CD4 and CD8 responses, enhanced by anti‐CD40 | Wang et al (2012); Charalambous et al (2006); Bonifaz et al (2004) |
| OVA epitope conjugated to anti‐DNGR‐1 (mouse or rat) | Mouse | B16 | Tumor inhibition and prevention; metastasis inhibition; enhanced antigen uptake by CD8α+ DCs | Sancho et al (2008) |
| Specific mIgG2a mAb/HER2‐neu | Mouse | Her2 transgenic mouse | IC‐mediated uptake of antigen by DCs; specific CD8 expansion; Fc required | Kim et al (2008); Wolpoe et al (2003) |
| Polyclonal rIgG/cell surface OVA | Mouse | Self‐antigen tolerance breaking | Breaking CD8 tolerance of OVA transgene; requires FcγR γ‐chain and complement C3 | Harbers et al (2007) |
| IgG2A (TA99)/Gp75 | Mouse | B16 | Tumor clearance; FcγRIV is required | Nimmerjahn and Ravetch (2005) |
| Specific mAb hIgG1 (B4‐B)/syndecan‐1 | Human | Myeloma | CTL induction to unrelated testis antigen epitopes; reduced with anti‐FcγR antibodies | Dhodapkar et al (2002) |
| Specific rIgG/OVA | Mouse | B16 (OVA expressing) | Mouse survival; FcR‐γ chain is required, absence of FcγIIB reduces tumor burden | Kalergis and Ravetch (2002) |
| Specific rIgG/OVA | Mouse | B16 (OVA expressing) | Reduced tumor establishment; FcγR‐γ required; TAP and β2m required; MHC class II required | Rafiq et al (2002) |
| Vaccine | ||||
| bNAb/Ebola GP | Macaque | Ebola | Protection against Ebola challenge, ADCC | Corti et al (2016) |
| bNAb/flu HA | Mouse | Influenza model | Protection against influenza challenge, ADCC | Wu et al (2015) |
| IgG/TIV | Mouse/human | Influenza | Early production of sialylated IgG set the threshold for subsequent high‐affinity and protective antibody production. | Wang et al (2015b) |
| Chicken polyclonal serum/NDV | Chicken | Newcastle disease | Protection against viral challenge; some preparations reduced protection | Yosipovich et al (2015); Rautenschlein et al (2007); Pokric et al (1993) |
| bNAb/HIV gp120 | Mouse (humanized) | HIV model | Longer period of aviremia after treatment; requires Fc portion for the effect | Halper‐Stromberg et al (2014) |
| Engineered bNAb/gp120 | Mouse (humanized) | HIV model | Better protection against HIV entry; bNAb with Fc engineered to bind activating FcγR (humanized in mouse) are more effective | Bournazos et al (2014) |
| Specific mIgG2a/FT | Mouse | Francisella tularensis | Protection from subsequent challenges | Pham et al (2014) |
| Humanized mAb/RSV | Cotton rat | RSV | G0 glycosylation is linked to better protection against RSV challenge | Hiatt et al (2014) |
| Pre‐made HBsAg IC | Human | HBV | Induction of specific IgG1 and IgG3; reduced serum HBV DNA; reduced serum HBeAg; presence of anti‐HBeAg; increased HBeAg seroconversion | Xu et al (2013); Yao et al (2007); Xu et al (2005) |
| HBsAg fused to Fc of mIgG2a | Mouse | HBV model | Higher specific CD8 activation; elevated CD4 response | Hong et al (2011) |
| Specific mIgG2a and mIgG1/FrCasE virus | Mouse | Model of HIV maternal transmission | Reduced adolescent mortality from the virus; ADCC and CTL activations are involved | Michaud et al (2010) |
| Human IgG mAb/CD4 binding site of gp120 | Mouse | HIV model | Higher anti‐gp120 titer; induction of neutralizing antibody | Hioe et al (2009); Visciano et al (2008) |
| Engineered specific hIgG1/P. falciparum | Mouse (humanized) | Plasmodium berghei | Protection from lethality; FcR‐binding/FcγRI are critical | McIntosh et al (2007) |
| Chicken polyclonal serum/IBDV | Chicken | Chicken Bursal Disease | Protection against viral challenge; immunization | Ivan et al (2005); Giambrone et al (2001); Jeurissen et al (1998); Haddad et al (1997) |
| IgG/HBsAg | Mouse | HBV model | HBsAb seroconversion in HBV transgenic mice | Zheng et al (2001) |
| Non‐neutralizing IgG fraction/SIV gp120 | Rhesus monkey | SIV | No protection, FcγRIIB signaling, anti‐inflammatory gene expression | Polyanskaya et al (2001) |
| Matrixed rat anti‐DHBV/DHBV | Duck | DHBV protection | Reduced viral DNA and DHBsAg in serum | Wen et al (1994) |
| IgG/anti‐gp120 v3 loop | Human | HIV | Positive anti‐HIV proliferation of CD4 T cells | Berzofsky et al (1988) |
| Human polyclonal IgG/HBV HBsAg | Human | In vitro antibody production | Enhanced CD4 T‐cell activation; enhanced antibody production; requires Fc | Celis et al (1987); Celis and Chang (1984); Celis et al (1984) |
| Rabbit IgG/human or bovine albumin | Mouse | Vaccine efficacy | Enhanced model antigen destruction in vivo | Terres and Wolins (1959a, 1961) |